Halkier-Sørensen L, Ternowitz T, Bjerring P, Poulsen JH, Alsbirk KE, Herlin T, Ravnsbaek J, Zachariae E, Zachariae H.
DOI: 10.2340/0001555566177179

Ten patients with systemic sclerosis were treated with benoxaprofen, a potent lipoxygenase inhibitor, for a period of 6 months. In an attempt to evaluate the efficacy a number of physical disease parameters were followed during the trial. None of these parameters revealed any significant differences. There was, however, a trend for a change towards normalisation of a defect monocyte chemotaxis. In view of the slow and progressive nature of systemic sclerosis the present study leaves undetermined whether benoxaprofen exerts a beneficial effect on systemic sclerosis.